Therapy-Associated Progressive Multifocal Leukoencephalopathy During Disease-Modifying Treatment of Multiple Sclerosis
Learning Objective: Discuss the clinical and imaging features that suggest a diagnosis of progressive multifocal leukoencephalopathy in MS-patients during long-term treatment with monoclonal antibodies.
Keywords: ANOVA = analysis of variance; CE = contrast-enhancement, contrast-enhanced; CSF = cerebrospinal fluid; DMT = disease modifying immunotherapy; DWI = diffusion-weighted imaging; FFE = fast field echo (gradient echo); FLAIR = fluid attenuated inversion recovery; FSE = fast spin-echo; HAART = high active antiretroviral therapy; IFN-β1a = Interferon beta-1a; IRIS = immune-reconstitution-inflammatory-syndrome; JCV = John-Cunningham-virus (human Polyomavirus); MS = multiple sclerosis; MTC = magnetization-transfer-contrast; MTR = magnetization-transfer ratio; NTZ = Natalizumab; NTZ-PML = Natalizumab-associated PML; PML = progressive multifocal leukoencephalopathy; ROI = region of interest; SE = spin-echo; T1-W IR = T1-weighted inversion-recovery
Document Type: Research Article
Publication date: 2016-11-01
Neurographics is the peer-reviewed, quarterly educational journal of the American Society of Neuroradiology. The journal comprises mainly articles created from select scientific exhibits at the ASNR Annual Meeting. Neurographics will also publish other high-quality submissions that are primarily educational and have a high emphasis on a pictorial approach. Articles are available free online, and a print-on-demand edition can be ordered from the Neurographics site.
- Editorial Board
- Information for Authors
- Membership Information
- Order a Print Copy
- Ingenta Connect is not responsible for the content or availability of external websites